Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Change in Accured Expenses data on file, last reported at -$716000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 63.71% year-over-year to -$716000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$951000.0 (up 66.28% YoY) and the FY2025 annual result came in at $58000.0, up 101.03% from the prior year.
• Change in Accured Expenses rose to -$716000.0 in Q1 2026, from -$5.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.7 million in Q2 2023 to a low of -$6.7 million in Q4 2023.
• A 5-year average of -$1.2 million and a median of -$716000.0 in 2026 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses slumped 277.88% — and 2025, when it surged 502.99%.
• Tracing ENTA's Change in Accured Expenses over 5 years: stood at -$6.6 million in 2022, then dropped by 2.08% to -$6.7 million in 2023, then soared by 56.8% to -$2.9 million in 2024, then plunged by 77.87% to -$5.2 million in 2025, then surged by 86.17% to -$716000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$716000.0 (Q1 2026), -$5.2 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.